Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination.
COVID-19 vaccines
cerebral venous sinus thrombosis
mortality
sinus thrombosis, intracranial
thrombocytopenia
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
06
09
2021
received:
13
08
2021
accepted:
09
09
2021
pubmed:
19
9
2021
medline:
15
12
2021
entrez:
18
9
2021
Statut:
ppublish
Résumé
High mortality rates have been reported in patients with cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) after vaccination with adenoviral vector SARS-CoV-2 vaccines. The aim of this study was to evaluate whether the mortality of patients with CVST-VITT has decreased over time. The EudraVigilance database of the European Medicines Agency was used to identify cases of CVST with concomitant thrombocytopenia occurring within 28 days of SARS-CoV-2 vaccination. Vaccines were grouped based on vaccine type (adenoviral or mRNA). Cases with CVST onset until 28 March were compared to cases after 28 March 2021, which was the day when the first scientific paper on VITT was published. In total, 270 cases of CVST with thrombocytopenia were identified, of which 266 (99%) occurred after adenoviral vector SARS-CoV-2 vaccination (ChAdOx1 nCoV-19, n = 243; Ad26.COV2.S, n = 23). The reported mortality amongst adenoviral cases with onset up to 28 March 2021 was 47/99 (47%, 95% confidence interval 37%-58%) compared to 36/167 (22%, 95% confidence interval 16%-29%) in cases with onset after 28 March (p < 0.001). None of the four cases of CVST with thrombocytopenia occurring after mRNA vaccination died. The reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-based SARS-CoV-2 vaccines has significantly decreased over time, which may indicate a beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.
Sections du résumé
BACKGROUND AND PURPOSE
High mortality rates have been reported in patients with cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) after vaccination with adenoviral vector SARS-CoV-2 vaccines. The aim of this study was to evaluate whether the mortality of patients with CVST-VITT has decreased over time.
METHODS
The EudraVigilance database of the European Medicines Agency was used to identify cases of CVST with concomitant thrombocytopenia occurring within 28 days of SARS-CoV-2 vaccination. Vaccines were grouped based on vaccine type (adenoviral or mRNA). Cases with CVST onset until 28 March were compared to cases after 28 March 2021, which was the day when the first scientific paper on VITT was published.
RESULTS
In total, 270 cases of CVST with thrombocytopenia were identified, of which 266 (99%) occurred after adenoviral vector SARS-CoV-2 vaccination (ChAdOx1 nCoV-19, n = 243; Ad26.COV2.S, n = 23). The reported mortality amongst adenoviral cases with onset up to 28 March 2021 was 47/99 (47%, 95% confidence interval 37%-58%) compared to 36/167 (22%, 95% confidence interval 16%-29%) in cases with onset after 28 March (p < 0.001). None of the four cases of CVST with thrombocytopenia occurring after mRNA vaccination died.
CONCLUSION
The reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-based SARS-CoV-2 vaccines has significantly decreased over time, which may indicate a beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.
Identifiants
pubmed: 34536256
doi: 10.1111/ene.15113
pmc: PMC8652752
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-344Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Eur J Neurol. 2022 Jan;29(1):339-344
pubmed: 34536256
Stroke. 2021 Jul;52(7):2478-2482
pubmed: 33914590
JAMA. 2021 Jul 27;326(4):332-338
pubmed: 34213527
Stroke. 2004 Mar;35(3):664-70
pubmed: 14976332
Eur J Neurol. 2021 Nov;28(11):3656-3662
pubmed: 34293217
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
N Engl J Med. 2021 Jun 10;384(23):2254-2256
pubmed: 33861524
J Thromb Haemost. 2017 Nov;15(11):2099-2114
pubmed: 28846826
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487